查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511791

外分泌胰臟功能不全诊断市场规模、份额、趋势分析报告：依诊断方法、最终用途、地区、细分市场预测，2024-2030年

Exocrine Pancreatic Insufficiency Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Method (Laboratory, Imaging), By End-use (Hospitals & Clinics, Research Institutes), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

外分泌胰臟功能不全诊断市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球外分泌胰臟功能不全诊断市场规模预计将达到54.4亿美元，2024年至2030年复合年增长率为7.2%。

胰臟外分泌功能不全 (EPI) 诊断对于该疾病的识别和治疗至关重要，特别是考虑到该疾病在不同患者群体中的高盛行率及其与多种根本原因的关联。诊断的主要促进因素之一是慢性胰臟炎患者的盛行率。研究表明，约 60% 至 90% 的慢性胰臟炎患者在诊断后 10 至 12 年内普遍存在 EPI。慢性胰臟炎是EPI的重要原因，其相对较高的盛行率凸显了早期发现和治疗的重要性。

此外，晚期胰臟癌也是与此疾病密切相关的疾病之一。研究表明，66% 至 92% 的晚期胰腺癌患者会出现 EPI。这些患者的 EPI 早期诊断可以更好地管理症状并提高生活品质。发炎性肠道疾病(IBD) 也与 EPI 相关，研究显示 14% 至 74% 的 IBD 患者可能会出现 EPI。及时诊断和治疗这些患者的外分泌胰臟功能不全，有助于缓解症状、改善营养状况。

此外，儘管服用酵素和营养食品，接受减重手术的患者仍有发生 EPI 的风险。这凸显了持续监测和诊断测试以确定该患者群体中胰臟外分泌功能不全的重要性。此外，爱滋病毒/爱滋病患者中 EPI 的盛行率估计为 26% 至 45%。早期发现这些患者的外分泌胰臟功能不全对于优化营养状况和整体健康结果至关重要。

与外分泌胰臟功能不全相关的多种病理强调需要全面的诊断方法。推动外分泌胰臟功能不全诊断剂需求的因素包括其在不同患者群体中的高盛行率、其与慢性胰臟炎和胰臟癌等慢性疾病的关联，以及对有效管理和改善患者预后的需求，其中包括早期诊断的重要性。诊断技术的进步将越来越多地实现早期检测和个人化管理，从而改善患者护理和治疗结果。

ChiRhoClin, Inc.、Certest Biotec、ScheBo Biotech AG、Immundiagnostik AG 和 Laboratory Corporation of America Holdings 等主要市场参与企业处于外分泌胰腺功能不全诊断创新的前沿。这些公司不断致力于扩大其产品范围。例如，2021年6月，CERTEST BIOTEC宣布将参加8月4日至8日在加州举行的第71届AACC年度学术会议和临床实验室展览会，展示其最新进展。

胰臟外分泌功能不全诊断市场报告亮点

  • 根据诊断方法，实验室检测领域在 2023 年以最高的收益占有率主导整个市场。这是由于实验室自动化、一次性套件、样本收集和储存、分析等方面的广泛进步。
  • EPI 诊断研发的扩大预计将在预测期内推动市场成长。
  • 新技术和检测方法的引入以及现有技术的整合代表了诊断学的重要进步。随着诊断技术进步的推动，人们对胰臟疾病的认识不断提高，用于 EPI 诊断的美国粪便检验市场预计将在未来几年继续扩大。
  • 由于多种因素，医院和诊所最终用途细分市场将在 2023 年占据市场主导地位。医疗保健专业人员和患者对症状和风险因素的认识不断提高，导致这些环境中诊断率的提高。医院和诊所诊断服务的便利性将使外分泌胰臟功能不全的筛检和检测变得广泛，诊断技术的进步将提高 EPI 检测的准确性和效率，进一步推动该领域的成长。
  • 由于先进的医疗基础设施、目标疾病盛行率上升以及有利的法规环境等因素，北美在市场上占据主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章外分泌胰臟功能不全诊断市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 胰臟外分泌功能不全诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析
    • 定量分析（实验室测试设备）

第四章胰臟外分泌功能不全诊断市场：诊断方法估算及趋势分析

  • 细分仪表板
  • 全球外分泌胰臟功能不全诊断市场波动分析
  • 依诊断方法分：全球外分泌胰臟功能不全诊断市场前景
  • 临床检查
  • 影像检查

第五章胰臟外分泌功能不全诊断市场：最终用途估计与趋势分析

  • 细分仪表板
  • 全球外分泌胰臟功能不全诊断市场波动分析
  • 全球外分泌胰臟功能不全诊断市场的最终用途与前景
  • 医院/诊所
  • 诊断实验室
  • 研究机构

第六章胰臟外分泌功能不全诊断市场：依诊断方法和最终用途进行区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • ChiRhoClin
    • Certest Biotec
    • ScheBo Biotech AG
    • Immundiagnostik AG
    • Laboratory Corporation of America Holdings
    • Boster Biological Technology
    • ALPCO Diagnostics
    • Quest Diagnostics Incorporated
    • DiaSorin SpA
    • ARUP Laboratories
    • Verisana Laboratories
    • Alpha Laboratories
Product Code: GVR-4-68040-294-6

Exocrine Pancreatic Insufficiency Diagnostics Market Growth & Trends:

The global exocrine pancreatic insufficiency diagnostics market size is anticipated to reach USD 5.44 billion by 2030 and is growing at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Exocrine pancreatic insufficiency (EPI) diagnostics are crucial for identifying and managing the condition, especially considering its high prevalence in various patient populations and its association with several underlying causes. One of the major driving factors for diagnostics is the prevalence of patients with chronic pancreatitis. Studies have shown that EPI is prevalent in about 60% to 90% of patients diagnosed with chronic pancreatitis within 10 to 12 years of diagnosis. Chronic pancreatitis is a significant contributor to EPI, and its relatively high prevalence underscores the importance of early detection and management.

Furthermore, advanced pancreatic cancer is another condition strongly associated with the disease. Research indicates that between 66% to 92% of patients with advanced pancreatic cancer develop EPI. Early diagnosis of EPI in these patients can lead to better management of symptoms and improved quality of life. Inflammatory bowel disease (IBD) is also linked to EPI, with studies suggesting that between 14% and 74% of IBD patients may suffer from EPI. Timely diagnosis and treatment of exocrine pancreatic insufficiency in these patients can help alleviate symptoms and improve nutritional status.

In addition, patients undergoing bariatric surgery are at risk of developing EPI despite receiving enzymatic and nutritional supplements. This highlights the importance of ongoing monitoring and diagnostic testing to identify exocrine pancreatic insufficiency in this patient population. Moreover, the prevalence of EPI in patients with HIV/AIDS is estimated to be between 26% and 45%. Early detection of exocrine pancreatic insufficiency in these individuals is essential for optimizing nutritional status and overall health outcomes.

The diverse range of conditions associated with EPI underscores the need for comprehensive diagnostic approaches. Factors driving the demand for exocrine pancreatic insufficiency diagnostics include high prevalence in various patient populations, the association with chronic conditions such as chronic pancreatitis and pancreatic cancer, and the importance of early detection for effective management and improved patient outcomes. As diagnostic technologies advance, early detection and personalized management will become increasingly feasible, leading to better patient care and outcomes.

Key market players such as ChiRhoClin, Inc., Certest Biotec, ScheBo Biotech AG, Immundiagnostik AG, and Laboratory Corporation of America Holdings are at the forefront of innovation in exocrine pancreatic insufficiency diagnostics. These companies are constantly focusing on expanding their products. For instance, in June 2021, CERTEST BIOTEC announced to participate and showcase its product with latest developments at 71st Annual Scientific Meeting and Exhibition of Clinical Laboratories of the AACC held from August 4 to 8 in California.

Exocrine Pancreatic Insufficiency Diagnostics Market Report Highlights:

  • Based on diagnostic method, the laboratory tests segment dominated the overall market with the highest revenue share in 2023. This can be attributed to the extensive advancements such as automation in the laboratory, disposable kits, sample collections & storage, and assays
  • Growing R&D in EPI diagnostics is projected to propel market growth over the forecast period
  • The introduction of new techniques and assays and the integration of established technologies signifies a significant step forward in diagnostics. As awareness about pancreatic disorders continues to grow, fueled by advancements in diagnostic technologies, the U.S. market for stool tests in EPI diagnostics is poised for continued expansion in the coming years
  • The hospitals and clinics end-use segment dominated the market in 2023, driven by several factors. Increased awareness among healthcare professionals and patients about symptoms and risk factors has led to higher diagnosis rates in these settings. Accessibility of diagnostic services in hospitals and clinics facilitates widespread screening and testing for exocrine pancreatic insufficiency, and advancements in diagnostic technologies enhance the accuracy and efficiency of EPI detection, further driving growth in this segment
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Diagnostic Method
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Diagnostic method Outlook
    • 2.2.2. End-use Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing disease awareness
      • 3.2.1.2. Focus on early detection
      • 3.2.1.3. Increasing cases of exocrine pancreatic insufficiency
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory hurdles and compliance requirements
      • 3.2.2.2. Underdiagnosis and misdiagnosis
  • 3.3. Exocrine Pancreatic Insufficiency Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Volume Analysis (Laboratory-based Testing Devices)

Chapter 4. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Exocrine Pancreatic Insufficiency Diagnostics Market Movement Analysis
  • 4.3. Global Exocrine Pancreatic Insufficiency Diagnostics Market by Diagnostic Method Outlook
  • 4.4. Laboratory Tests
    • 4.4.1. Laboratory tests market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Indirect Pancreatic Function Tests
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.2. Stool Tests
      • 4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.3. Blood Tests
      • 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Other Tests
      • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Imaging Tests
    • 4.5.1. Imaging tests market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2. CT scans
      • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.3. MRI
      • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.4. Endoscopic Ultrasound for pancreatic function tests
      • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Exocrine Pancreatic Insufficiency Diagnostics Market Movement Analysis
  • 5.3. Global Exocrine Pancreatic Insufficiency Diagnostics Market by End-use Outlook
  • 5.4. Hospitals & Clinics
    • 5.4.1. Hospitals & Clinics market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Diagnostic laboratories market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Research Institutes
    • 5.6.1. Research Institutes market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Exocrine Pancreatic Insufficiency Diagnostics Market: Regional Estimates & Trend Analysis by Diagnostic Method, and End-use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. ChiRhoClin
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Certest Biotec
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. ScheBo Biotech AG
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Immundiagnostik AG
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Laboratory Corporation of America Holdings
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Boster Biological Technology
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. ALPCO Diagnostics
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Quest Diagnostics Incorporated
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. DiaSorin S.p.A.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. ARUP Laboratories
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Verisana Laboratories
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Alpha Laboratories
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 4 North America exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 6 U.S. exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 8 Canada exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 11 Europe exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Germany exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 13 Germany exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 UK exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 15 UK exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 France exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 17 France exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Italy exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 19 Italy exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 21 Spain exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Denmark exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 23 Denmark exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Sweden exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 25 Sweden exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Norway exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 27 Norway exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific exocrine pancreatic insufficiency diagnostics market, by region 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 30 Aisa Pacific exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Japan exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 32 Japan exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 China exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 34 China exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 India exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 36 India exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Australia exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 38 Australia exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Thailand exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 40 Thailand exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 South Korea exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 42 South Korea exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 45 Latin America exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Brazil exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 47 Brazil exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Mexico exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 49 Mexico exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Argentina exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 51 Argentina exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 MEA exocrine pancreatic insufficiency diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 54 MEA exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 South Africa exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 56 South Africa exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 UAE exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 60 UAE exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait exocrine pancreatic insufficiency diagnostics market, by diagnostic method, 2018 - 2030 (USD Million)
  • Table 62 Kuwait exocrine pancreatic insufficiency diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in Asia Pacific
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Exocrine pancreatic insufficiency diagnostics market: market outlook
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Exocrine pancreatic insufficiency diagnostics market driver impact
  • Fig. 17 Exocrine pancreatic insufficiency diagnostics market restraint impact
  • Fig. 18 Exocrine pancreatic insufficiency diagnostics market: Diagnostic method movement analysis
  • Fig. 19 Exocrine pancreatic insufficiency diagnostics market: Diagnostic method outlook and key takeaways
  • Fig. 20 Laboratory tests market estimates and forecast, 2018 - 2030
  • Fig. 21 Indirect pancreatic function tests market estimates and forecast, 2018 - 2030
  • Fig. 22 Stool tests market estimates and forecast, 2018 - 2030
  • Fig. 23 Blood tests market estimates and forecast, 2018 - 2030
  • Fig. 24 Other tests market estimates and forecast, 2018 - 2030
  • Fig. 25 Imaging tests market estimates and forecast, 2018 - 2030
  • Fig. 26 CT scans market estimates and forecast, 2018 - 2030
  • Fig. 27 MRI market estimates and forecast, 2018 - 2030
  • Fig. 28 Endoscopic ultrasound for pancreatic function tests market estimates and forecast, 2018 2030
  • Fig. 29 Exocrine pancreatic insufficiency diagnostics market: End-use movement analysis
  • Fig. 30 Exocrine pancreatic insufficiency diagnostics market: End-use outlook and key takeaways
  • Fig. 31 Hospitals & clinics market estimates and forecast, 2018 - 2030
  • Fig. 32 Diagnostic laboratories estimates and forecast, 2018 - 2030
  • Fig. 33 Research institutes market estimates and forecast, 2018 - 2030
  • Fig. 34 Global Exocrine pancreatic insufficiency diagnostics market: Regional movement analysis
  • Fig. 35 Global Exocrine pancreatic insufficiency diagnostics market: Regional outlook and key takeaways
  • Fig. 36 Global Exocrine pancreatic insufficiency diagnostics market share and leading players
  • Fig. 37 North America
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 China key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Japan key country dynamics
  • Fig. 66 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand key country dynamics
  • Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 South Korea key country dynamics
  • Fig. 74 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America
  • Fig. 76 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico key country dynamics
  • Fig. 80 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa
  • Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Africa key country dynamics
  • Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Saudi Arabia key country dynamics
  • Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 UAE key country dynamics
  • Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Kuwait key country dynamics
  • Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Market share of key market players- Exocrine pancreatic insufficiency diagnostics market